ClinicalTrials.gg
CompletedNCT03483961Updated Jul 3, 2023Results posted

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

A Phase 2 interventional study of CHIKV VLP/unadjuvanted and CHIKV VLP/adjuvanted in Chikungunya Virus Infection, sponsored by Bavarian Nordic. Completed at 3 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Bavarian Nordic · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
445
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Chikungunya Fever with a site in United States — 1 open to participants now, 4 under way, 3 of them phase 3. Chikungunya Fever · United States.

Enrollment
5th of 16
445 · median 272
Started
2018
with 2 others
Phase 2
2 of 18
none open now
Registered
5th of 18
by date
Lead sponsor
6 of 18
Bavarian Nordic

Among the 18 studies in Chikungunya Fever with a site in United States, this one is the 5th largest by enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2, and was the 5th registered.

Chikungunya Fever

88 studies on the registry are indexed under Chikungunya Fever; 21 are open to participants now.

Browse Chikungunya Fever studies →

Open to participants now

1 of the 18 studies in Chikungunya Fever with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 8 Chikungunya Fever studies recruiting now, 5 set no upper age limit and 3 stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Chikungunya Fever with a site in United States, or all of them as a file.
02

Study summary

The goal of this Phase 2 trial is to evaluate the immune response to and safety profile of various doses/formulations/and schedules of administration of PXVX0317 in healthy adults.

Primary Objective:

To assess the immune response to the vaccine

Secondary Objectives:

To assess the kinetics of the immune response to different doses/formulations/schedules To assess the persistence of immune responses to different doses/formulations/schedules To assess the effect of a booster dose of the vaccine

Safety Objective:

To assess local and systemic reactions to the vaccine and to describe the safety profile of the vaccine

Read the detailed description

The trial will explore 8 formulation/schedule combinations of CHIKV VLP vaccine with or without Alhydrogel adjuvant, and will also explore different dose schedules of Day 1 and 15 or Day 1 and 29 or Day 29 only.

03

Conditions studied

  • Chikungunya Virus Infection

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female
  2. Age 18 to 45 years old (inclusive)
  3. Using an acceptable method of (if female of ).
  4. Able and willing to provide for study participation.

Exclusion criteria

Exclusion Criteria:

  1. Current acute febrile illness.
  2. cardiac, respiratory, or rheumatologic disease, in the opinion of the Investigator.
  3. Pregnant or breast-feeding.
  4. Laboratory evidence of infection with /C or .
  5. History of chikungunya virus infection.
  6. Travel to a World Health Organization-designated chikungunya-endemic region within 30 days prior to Day 1.
  7. History of allergic reaction to any component of CHIKV-VLP vaccine, Diluent, or Alhydrogel®.
  8. Inability to discontinue systemic immunomodulatory or medications 30 days prior to Day 1.
  9. Received or plans to receive any licensed vaccine from 30 days prior to Day 1 through Day 57.
  10. Received or plans to receive an agent from 30 days prior to Day 1 through the duration of study participation.
  11. Any other condition that, in the opinion of the Investigator, creates an unacceptable risk to the subject.
  12. Any other condition that, in the opinion of the Investigator, may interfere with the conduct of the study or the validity of the data.
  13. Any other condition that, in the opinion of the Investigator, creates an unacceptable safety risk for apheresis (Group 9 \& 10 only).
  14. Restricted venous access that would prevent the collection of PBMCs, plasma, and lymphocytes necessary for participation (Group 9 \& 10 only).
  15. Weight \< 110 pounds (Group 9 \& 10 only)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
445 participants (actual)

Study arms

  • Experimental
    Group 1: 20 mcg/unadjuvanted (Day 1 & 29)

    20 mcg CHIKV VLP/unadjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/unadjuvanted (Day 29)

    Biological: CHIKV VLP/unadjuvanted · Biological: Placebo

  • Experimental
    Group 2: 6 mcg/adjuvanted (Day 1 & 29)

    6 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)

    Biological: CHIKV VLP/adjuvanted · Biological: Placebo

  • Experimental
    Group 3: 10 mcg/adjuvanted (Day 1 & 29)

    10 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)

    Biological: CHIKV VLP/adjuvanted · Biological: Placebo

  • Experimental
    Group 4: 20mcg/adjuvanted (Day 1 & 29);40mcg/adjuvant (Day 547)

    20 mcg CHIKV VLP/adjuvanted (Day 1) // Placebo (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29) // 40 mcg CHIKV (Day 547)

    Biological: CHIKV VLP/adjuvanted · Biological: Placebo

  • Experimental
    Group 5: 6 mcg/adjuvanted (Day 15 & 29)

    Placebo (Day 1) // 6 mcg CHIKV VLP/adjuvanted (Day 15) // 6 mcg CHIKV VLP/adjuvanted (Day 29)

    Biological: CHIKV VLP/adjuvanted · Biological: Placebo

  • Experimental
    Group 6: 10 mcg/adjuvanted (Day 15 & 29)

    Placebo (Day 1) // 10 mcg CHIKV VLP/adjuvanted (Day 15) // 10 mcg CHIKV VLP/adjuvanted (Day 29)

    Biological: CHIKV VLP/adjuvanted · Biological: Placebo

  • Experimental
    Group 7: 20 mcg/adjuvanted (Day 15 & 29)

    Placebo (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 15) // 20 mcg CHIKV VLP/adjuvanted (Day 29)

    Biological: CHIKV VLP/adjuvanted · Biological: Placebo

  • Experimental
    Group 8: 40 mcg/adjuvanted (Day 29)

    Placebo (Day 1) // Placebo (Day 15) // 40 mcg CHIKV VLP/adjuvanted (Day 29)

    Biological: CHIKV VLP/adjuvanted · Biological: Placebo

  • Experimental
    Group 9: 20 mcg/adjuvanted (Day 1 & 29)

    20 mcg CHIKV VLP/adjuvanted (Day 1) // 20 mcg CHIKV VLP/adjuvanted (Day 29). This group will also have plasmapheresis performed on Day 57 and Leukapheresis on Day 182

    Biological: CHIKV VLP/adjuvanted

  • Experimental
    Group 10: 40 mcg/adjuvanted (Day 1)

    40 mcg CHIKV VLP/adjuvanted (Day 1). This group will also have plasmapheresis performed on Day 22.

    Biological: CHIKV VLP/adjuvanted

Interventions

  • BiologicalCHIKV VLP/unadjuvanted

    Vaccine consists of virus-like particles of chikungunya virus antigens

  • BiologicalCHIKV VLP/adjuvanted

    Adjuvanted formulation includes Alhydrogel

  • BiologicalPlacebo

    Placebo is vaccine diluent alone

06

What researchers measure

Primary outcomes

  1. Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.

    To assess the induction of anti-chikungunya virus (CHIKV) neutralizing antibody geometric mean titers by different formulations and schedules, as measured at 28 days after the last injection (Day 57) for Groups 2-8.

    Time frame: Day 57 (from Day 1 vaccination), 28 days after the last injection.

Secondary outcomes

  1. Kinetics of Anti-chikungunya Virus (CHIKV) Neutralizing Antibody Geometric Mean Titer for Groups 2-8.

    To describe the kinetics of induction of anti-CHIKV neutralizing antibody geometric mean titers by different formulations and schedules for Groups 2-8.

    Time frame: At Days 8, 15, 22, 29, 36, and 57.

  2. Differences in Persistence of Neutralizing Antibody Geometric Mean Titer for Groups 2-8.

    To assess differences in persistence of neutralizing antibody geometric mean titers induced by different formulations and schedules, as measured up to 731 days after the last injection (Day 760) relative to earlier time points for Groups 2-8.

    Time frame: At Days 182, 365, 547, and 760.

  3. Boosting of Vaccine-induced Neutralizing Antibody Geometric Mean Titer by a Booster Dose of PXVX0317 for Group 4 Only.

    To assess the effect of a booster dose of PXVX0317 on neutralizing antibody geometric mean titers when given at Day 547 for Group 4 only. Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.

    Time frame: Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.

  4. Percentage of Participants With an Anti-CHIKV Neutralizing Antibody Titer Exceeding the Following Cutoff Values: ≥15, 40, 160, 640, and 4-fold Rise Over Baseline.

    Percentage of participants with an anti-CHIKV neutralizing antibody titer exceeding the following cutoff values: ≥15, 40, 160, 640, and 4-fold rise over baseline.

    Time frame: Day 57 (from Day 1 vaccination), 28 days after the last injection.

07

Results

Posted Nov 9, 2021

Participant flow

Participants were recruited at 3 U.S. sites.

Participant flow — Overall Study
MilestoneGroup 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)
Started53525150535351522010
Exposed / safety53525051535351522010
Immunogenicity-evaluable47444445484847502010
Completed42423941434746391810
Not completed111012910651320
Withdrew: Lost to follow-up76666441110
Withdrew: Withdrawal by subject3453421210
Withdrew: Other than ae, death, pi decision, ltfu, noncompliance, study terminated, or withdrawal of consent1000000000
Withdrew: Adverse event0010000000

Outcome measures

PrimaryAnti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.

To assess the induction of anti-chikungunya virus (CHIKV) neutralizing antibody geometric mean titers by different formulations and schedules, as measured at 28 days after the last injection (Day 57) for Groups 2-8.

Time frame:
Day 57 (from Day 1 vaccination), 28 days after the last injection.
Reported as:
Geometric mean · titer
Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.
titerGroup 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)
Anti-CHIKV Neutralizing Antibody Geometric Mean Titer 28 Days After the Last Injection for Groups 2-8.2057.0 (1584.8 to 2670.0)1116.2 (852.5 to 1461.4)1465.3 (1119.1 to 1918.4)2023.8 (1550.5 to 2641.7)920.1 (710.9 to 1190.9)1206.9 (932.4 to 1562.2)1562.8 (1204.1 to 2028.3)1712.5 (1330.0 to 2205.0)
Statistical analysis
  • Group 1: 20 mcg/Unadjuvant (Day 1 & 29) vs Group 2: 6 mcg/Adjuvant (Day 1 & 29) vs Group 3: 10 mcg/Adjuvant (Day 1 & 29) vs Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) vs Group 5: 6 mcg/Adjuvant (Day 15 & 29) vs Group 6: 10 mcg/Adjuvant (Day 15 & 29) vs Group 7: 20 mcg/Adjuvant (Day 15 & 29) vs Group 8: 40 mcg/Adjuvant (Day 29) · ANOVA · p = 0.0015 (All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.)ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 2 vs. Group 1.
  • Group 1: 20 mcg/Unadjuvant (Day 1 & 29) vs Group 2: 6 mcg/Adjuvant (Day 1 & 29) vs Group 3: 10 mcg/Adjuvant (Day 1 & 29) vs Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) vs Group 5: 6 mcg/Adjuvant (Day 15 & 29) vs Group 6: 10 mcg/Adjuvant (Day 15 & 29) vs Group 7: 20 mcg/Adjuvant (Day 15 & 29) vs Group 8: 40 mcg/Adjuvant (Day 29) · ANOVA · p = 0.0761 (All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.)ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 3 vs. Group 1.
  • Group 1: 20 mcg/Unadjuvant (Day 1 & 29) vs Group 2: 6 mcg/Adjuvant (Day 1 & 29) vs Group 3: 10 mcg/Adjuvant (Day 1 & 29) vs Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) vs Group 5: 6 mcg/Adjuvant (Day 15 & 29) vs Group 6: 10 mcg/Adjuvant (Day 15 & 29) vs Group 7: 20 mcg/Adjuvant (Day 15 & 29) vs Group 8: 40 mcg/Adjuvant (Day 29) · ANOVA · p = 0.9317 (All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.)ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 4 vs. Group 1.
  • Group 1: 20 mcg/Unadjuvant (Day 1 & 29) vs Group 2: 6 mcg/Adjuvant (Day 1 & 29) vs Group 3: 10 mcg/Adjuvant (Day 1 & 29) vs Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) vs Group 5: 6 mcg/Adjuvant (Day 15 & 29) vs Group 6: 10 mcg/Adjuvant (Day 15 & 29) vs Group 7: 20 mcg/Adjuvant (Day 15 & 29) vs Group 8: 40 mcg/Adjuvant (Day 29) · ANOVA · p = <.0001 (All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.)ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 5 vs. Group 1.
  • Group 1: 20 mcg/Unadjuvant (Day 1 & 29) vs Group 2: 6 mcg/Adjuvant (Day 1 & 29) vs Group 3: 10 mcg/Adjuvant (Day 1 & 29) vs Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) vs Group 5: 6 mcg/Adjuvant (Day 15 & 29) vs Group 6: 10 mcg/Adjuvant (Day 15 & 29) vs Group 7: 20 mcg/Adjuvant (Day 15 & 29) vs Group 8: 40 mcg/Adjuvant (Day 29) · ANOVA · p = 0.0045 (All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.)ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 6 vs. Group 1.
  • Group 1: 20 mcg/Unadjuvant (Day 1 & 29) vs Group 2: 6 mcg/Adjuvant (Day 1 & 29) vs Group 3: 10 mcg/Adjuvant (Day 1 & 29) vs Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) vs Group 5: 6 mcg/Adjuvant (Day 15 & 29) vs Group 6: 10 mcg/Adjuvant (Day 15 & 29) vs Group 7: 20 mcg/Adjuvant (Day 15 & 29) vs Group 8: 40 mcg/Adjuvant (Day 29) · ANOVA · p = 0.1437 (All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.)ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 7 vs. Group 1.
  • Group 1: 20 mcg/Unadjuvant (Day 1 & 29) vs Group 2: 6 mcg/Adjuvant (Day 1 & 29) vs Group 3: 10 mcg/Adjuvant (Day 1 & 29) vs Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547) vs Group 5: 6 mcg/Adjuvant (Day 15 & 29) vs Group 6: 10 mcg/Adjuvant (Day 15 & 29) vs Group 7: 20 mcg/Adjuvant (Day 15 & 29) vs Group 8: 40 mcg/Adjuvant (Day 29) · ANOVA · p = 0.3216 (All tests were carried out at a 2-sided significance level of 0.05 and no adjustment for multiplicity was applied, since the goal was to rank different formulations rather than to establish inferential values.)ANOVA model including site and treatment group as fixed effects assuming normality of log titers. P-value is for Group 8 vs. Group 1.
SecondaryKinetics of Anti-chikungunya Virus (CHIKV) Neutralizing Antibody Geometric Mean Titer for Groups 2-8.

To describe the kinetics of induction of anti-CHIKV neutralizing antibody geometric mean titers by different formulations and schedules for Groups 2-8.

Time frame:
At Days 8, 15, 22, 29, 36, and 57.
Reported as:
Geometric mean · titer
Kinetics of Anti-chikungunya Virus (CHIKV) Neutralizing Antibody Geometric Mean Titer for Groups 2-8.
titerGroup 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)
Day 870.6 (53.2 to 93.7)34.3 (25.6 to 46.1)72.6 (54.2 to 97.2)117.6 (87.8 to 157.4)8.4 (6.3 to 11.1)7.5 (5.7 to 10.0)7.5 (5.7 to 10.0)7.5 (5.7 to 9.9)
Day 15419.3 (323.6 to 543.4)189.4 (144.9 to 247.6)530.2 (405.6 to 693.0)912.7 (700.4 to 1189.5)7.7 (6.0 to 10.0)7.5 (5.8 to 9.7)7.7 (5.9 to 9.9)7.5 (5.8 to 9.6)
Day 22691.5 (499.2 to 957.9)351.3 (250.9 to 492.0)1400.2 (999.9 to 1960.8)2198.1 (1575.6 to 3066.5)46.4 (33.6 to 64.1)63.1 (45.7 to 87.1)119.0 (85.9 to 164.9)7.5 (5.5 to 10.3)
Day 29417.2 (305.4 to 570.0)277.3 (200.9 to 382.8)890.5 (645.1 to 1229.2)1238.1 (900.2 to 1702.9)258.0 (189.5 to 351.3)328.8 (241.5 to 447.6)886.2 (648.7 to 1210.5)8.2 (6.0 to 11.0)
Day 363442.8 (2533.9 to 4677.8)1675.8 (1220.9 to 2300.2)2772.4 (2019.8 to 3805.4)3435.0 (2511.4 to 4698.1)1327.7 (980.4 to 1797.9)2155.4 (1591.6 to 2919.0)3609.0 (2647.7 to 4919.3)157.9 (117.3 to 212.6)
Day 572057.0 (1584.8 to 2670.0)1116.2 (852.5 to 1461.4)1465.3 (1119.1 to 1918.4)2023.8 (1550.5 to 2641.7)920.1 (710.9 to 1190.9)1206.9 (932.4 to 1562.2)1562.8 (1204.1 to 2028.3)1712.5 (1330.0 to 2205.0)
SecondaryDifferences in Persistence of Neutralizing Antibody Geometric Mean Titer for Groups 2-8.

To assess differences in persistence of neutralizing antibody geometric mean titers induced by different formulations and schedules, as measured up to 731 days after the last injection (Day 760) relative to earlier time points for Groups 2-8.

Time frame:
At Days 182, 365, 547, and 760.
Reported as:
Geometric mean · titer
Differences in Persistence of Neutralizing Antibody Geometric Mean Titer for Groups 2-8.
titerGroup 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)
Day 182345.1 (258.1 to 461.3)209.0 (153.1 to 285.2)358.4 (261.6 to 491.2)486.6 (360.5 to 656.9)253.4 (188.4 to 340.9)303 (226.7 to 405.0)388.1 (291.3 to 517.1)505.7 (380.7 to 671.8)
Day 365243.4 (176.8 to 334.9)137.5 (98.3 to 192.3)226.7 (160.6 to 320.0)336.6 (244.6 to 463.2)195.2 (141.3 to 269.6)246.9 (180.1 to 338.4)302.0 (220.3 to 414.0)491.7 (362.5 to 667.0)
Day 547169.2 (126.2 to 226.8)NA (NA to NA)NA (NA to NA)215.7 (160.9 to 289.1)NA (NA to NA)NA (NA to NA)NA (NA to NA)297.9 (221.4 to 400.8)
Day 760169.8 (122.4 to 235.5)NA (NA to NA)NA (NA to NA)5365.1 (3853.2 to 7470.1)NA (NA to NA)NA (NA to NA)NA (NA to NA)279.7 (200.1 to 391.1)
SecondaryBoosting of Vaccine-induced Neutralizing Antibody Geometric Mean Titer by a Booster Dose of PXVX0317 for Group 4 Only.

To assess the effect of a booster dose of PXVX0317 on neutralizing antibody geometric mean titers when given at Day 547 for Group 4 only. Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.

Time frame:
Antibody levels will be measured at Day 547 prior to the booster dose and again 28 days later on Day 575 and then at Day 760.
Reported as:
Geometric mean · titer
Boosting of Vaccine-induced Neutralizing Antibody Geometric Mean Titer by a Booster Dose of PXVX0317 for Group 4 Only.
titerGroup 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)
Day 547 (pre-boost)223.6 (166.7 to 299.9)
Day 575 (post-boost)12325.8 (8951.4 to 16972.4)
Day 760 (post-boost)5874.2 (4269.4 to 8082.3)
SecondaryPercentage of Participants With an Anti-CHIKV Neutralizing Antibody Titer Exceeding the Following Cutoff Values: ≥15, 40, 160, 640, and 4-fold Rise Over Baseline.

Percentage of participants with an anti-CHIKV neutralizing antibody titer exceeding the following cutoff values: ≥15, 40, 160, 640, and 4-fold rise over baseline.

Time frame:
Day 57 (from Day 1 vaccination), 28 days after the last injection.
Reported as:
Count of participants · Participants
Percentage of Participants With an Anti-CHIKV Neutralizing Antibody Titer Exceeding the Following Cutoff Values: ≥15, 40, 160, 640, and 4-fold Rise Over Baseline.
ParticipantsGroup 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)
Titer at or above 154744444548484750
Titer at or above 404744434548484750
Titer at or above 1604742434547484650
Titer at or above 6404332414329404144
Titer at or above 4-fold rise over baseline4744434548484750

Adverse events

Collected over Unsolicited adverse events were monitored through Day 760 (Groups 1, 4, and 8), Day 365 (Groups 2, 3, 5, 6, and 7), Day 182 (Group 9), and Day 29 (Group 10), but only unsolicited adverse events occurring through Day 57 (end of treatment and observation period, 28 days after last dose for Groups 1-8) are reported.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: 20 mcg/Unadjuvant (Day 1 & 29)0/53 (0%)0/53 (0%)26/53 (49.1%)
Group 2: 6 mcg/Adjuvant (Day 1 & 29)0/52 (0%)1/52 (1.9%)35/52 (67.3%)
Group 3: 10 mcg/Adjuvant (Day 1 & 29)0/50 (0%)2/50 (4%)36/50 (72%)
Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)0/51 (0%)1/51 (2%)34/51 (66.7%)
Group 5: 6 mcg/Adjuvant (Day 15 & 29)0/53 (0%)0/53 (0%)29/53 (54.7%)
Group 6: 10 mcg/Adjuvant (Day 15 & 29)0/53 (0%)0/53 (0%)28/53 (52.8%)
Group 7: 20 mcg/Adjuvant (Day 15 & 29)0/51 (0%)2/51 (3.9%)30/51 (58.8%)
Group 8: 40 mcg/Adjuvant (Day 29)0/52 (0%)3/52 (5.8%)34/52 (65.4%)
Group 9: 20 mcg/Adjuvant (Day 1 & 29)0/20 (0%)0/20 (0%)12/20 (60%)
Group 10: 40 mcg/Adjuvant (Day 1)0/10 (0%)0/10 (0%)4/10 (40%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventGroup 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)
Anaphylactic reactionImmune system disorders0/530/521/500/510/530/530/510/520/200/10
Road traffic accidentInjury, poisoning and procedural complications0/530/521/500/510/530/530/510/520/200/10
GastroenteritisInfections and infestations0/530/520/500/510/530/531/510/520/200/10
Laryngeal injuryInjury, poisoning and procedural complications0/530/520/501/510/530/530/510/520/200/10
Hyperemesis gravidarumPregnancy, puerperium and perinatal conditions0/530/520/500/510/530/531/510/520/200/10
Premature separation of placentaPregnancy, puerperium and perinatal conditions0/530/520/500/510/530/531/510/520/200/10
Threatened labourPregnancy, puerperium and perinatal conditions0/530/520/500/510/530/531/510/520/200/10
Vaginal haemorrhageReproductive system and breast disorders0/530/520/500/510/530/531/510/520/200/10
Biliary dyskinesiaHepatobiliary disorders0/530/520/500/510/530/530/511/520/200/10
AppendicitisInfections and infestations0/530/520/500/510/530/530/511/520/200/10
Most frequent other events
Showing 10 of 15
Most frequent other events
EventGroup 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)
Injection site pain, solicitedGeneral disorders19/5327/5223/5029/5118/5318/5318/5126/5210/202/10
Myalgia, solicitedMusculoskeletal and connective tissue disorders11/5312/5212/5021/5111/5310/5311/5111/520/202/10
Headache, solicitedNervous system disorders11/5314/5218/5020/5111/5311/5314/5119/523/201/10
Fatigue, solicitedGeneral disorders11/5312/5212/5019/517/537/5311/5110/522/202/10
Nausea, solicitedGastrointestinal disorders8/536/528/5014/514/535/536/516/521/200/10
Malaise, solicitedGeneral disorders7/537/526/5014/514/537/5310/519/522/201/10
Arthralgia, solicitedMusculoskeletal and connective tissue disorders3/539/524/5012/513/534/534/516/521/201/10
Chills, solicitedGeneral disorders1/533/525/508/513/534/534/513/520/200/10
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/530/520/502/510/530/530/510/520/201/10
GastroenteritisInfections and infestations0/531/521/500/510/530/534/511/520/200/10

Baseline characteristics

Randomized participants.

Age, Categorical
Age, Categorical(Participants)Group 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)Total
<=18 years31000100005
Between 18 and 65 years50515150535251522010440
>=65 years00000000000
Age, Continuous
Age, Continuous(years)Group 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)Total
Mean30.4 ± 8.2231.2 ± 8.2631.2 ± 7.6433.7 ± 7.5330.6 ± 7.7232.9 ± 7.5332.4 ± 7.7831.6 ± 7.8227.1 ± 7.5829.6 ± 7.6531.5 ± 7.86
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)Total
Female303037323829272673259
Male2322141815242426137186
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)Total
Hispanic or Latino344348242135
Not Hispanic or Latino5048474749454948189410
Unknown or Not Reported00000000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)Total
American Indian or Alaska Native00000100102
Asian02120102109
Native Hawaiian or Other Pacific Islander00001010002
Black or African American109141314915776104
White4340363536403441114320
More than one race01002212008
Unknown or Not Reported00000000000
Region of Enrollment
Region of Enrollment(participants)Group 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)Total
United States53525150535351522010445
Day 1 predose (baseline) geometric mean anti-chikungunya luciferase neutralizing antibody titer.
Day 1 predose (baseline) geometric mean anti-chikungunya luciferase neutralizing antibody titer.(titer)Group 1: 20 mcg/Unadjuvant (Day 1 & 29)Group 2: 6 mcg/Adjuvant (Day 1 & 29)Group 3: 10 mcg/Adjuvant (Day 1 & 29)Group 4: 20mcg/Adjuvant(Day 1 & 29);40mcg/Adjuvant (Day 547)Group 5: 6 mcg/Adjuvant (Day 15 & 29)Group 6: 10 mcg/Adjuvant (Day 15 & 29)Group 7: 20 mcg/Adjuvant (Day 15 & 29)Group 8: 40 mcg/Adjuvant (Day 29)Group 9: 20 mcg/Adjuvant (Day 1 & 29)Group 10: 40 mcg/Adjuvant (Day 1)Total
Geometric mean7.5 (7.5 to 7.5)7.5 (7.5 to 7.5)7.5 (7.5 to 7.5)7.5 (7.5 to 7.5)7.8 (7.5 to 50.3)7.5 (7.5 to 7.5)7.5 (7.5 to 7.5)7.5 (7.5 to 7.5)8.6 (7.5 to 117.1)9.0 (7.5 to 46.1)7.6 (7.5 to 117.1)
08

Study locations

3 sites
  • Johnson County Clin-Trials
    Lenexa, Kansas 66219, United States
  • The Center for Pharmaceutical Research
    Kansas City, Missouri 64114, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
09

References and documents

Publications

  • Bennett SR, McCarty JM, Ramanathan R, Mendy J, Richardson JS, Smith J, Alexander J, Ledgerwood JE, de Lame PA, Royalty Tredo S, Warfield KL, Bedell L. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial. Lancet Infect Dis. 2022 Sep;22(9):1343-1355. doi: 10.1016/S1473-3099(22)00226-2. Epub 2022 Jun 13. PubMed 35709798 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Sep 2020, 28 months.

Results were first posted in Nov 2021, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2018
First posted
Mar 30, 2018
StartActual
Apr 18, 2018
Primary completionActual
Sep 14, 2020
CompletionActual
Sep 21, 2020
Results first posted
Nov 9, 2021
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03483961
Lead sponsor
Bavarian Nordic
Responsible party
Sponsor
First posted
Mar 30, 2018
Start date
Apr 18, 2018
Primary completion
Sep 14, 2020
Completion
Sep 21, 2020
Results posted
Nov 9, 2021
Last update
Jul 3, 2023

Study contacts

James McCarty, MD
study director · Emergent BioSolutions

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion